CureVac N.V.
CVAC
ISIN NL0015436031 / Valor 56537572
CureVac N.V.
UMushroom community rating:
About company
CureVac N.V. is a clinical-stage biotechnology company based in Germany that develops messenger RNA (mRNA) technologies for prophylactic vaccines and therapeutic applications, including oncology and rare diseases. The company builds and commercializes platform capabilities for mRNA design, formulation and manufacturing, and advances programs through preclinical and clinical development while partnering with larger pharmaceutical firms to accelerate development and scale production. CureVac gained broad attention for an early-generation COVID-19 vaccine candidate that produced disappointing efficacy in late-stage testing, after which the company pivoted toward next‑generation mRNA constructs and diversified therapeutic programs. It remains a publicly traded developer of mRNA-based medicines, focused on turning platform know-how and manufacturing capacity into clinical-stage assets and partnered programs.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
1121 M
Market cap (USD)
Daily traded volume (Shares)
3.22 / 3.04
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
